Trimodality Approach to Unfavorable Localized Prostate Cancer: a prospective trial of Neoadjuvant Pembrolizumab, ADT, and Prostate SBRT followed by Radical Prostatectomy
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck & Co., Inc.
Start Date
January 28, 2021
End Date
October 15, 2025
Administered By
Duke Cancer Institute
Awarded By
Merck & Co., Inc.
Start Date
January 28, 2021
End Date
October 15, 2025